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Abstract: Dysbiosis has been associated with the onset of several chronic autoimmune or inflammatory
pathologies (e.g., inflammatory bowel diseases—IBD), because of its primary role in the establishment
of a chronic inflammatory process leading to tissue damage. Inflammatory bowel diseases can even
involve areas far away from the gut, such as the extraintestinal manifestations involving the oral
cavity with the onset of aphthous-like ulcers (ALU). Studies carried out on animal models have
shown that intestinal dysbiosis may be related to the development of autoimmune diseases, even if
the mechanisms involved are not yet well known. The aim of this paper is to verify the hypothesis
that in inflammatory bowel diseases patients, aphthous-like ulcers are the result of the concomitance
of intestinal dysbiosis and other events, e.g., the microtraumas, occurring in the oral mucosa, and
that ex adiuvantibus therapy with probiotics can be employed to modify the natural course of the
aphthous-like ulcers.
Keywords: microbiota; muco-microbiotic layer; dysbiosis; inflammatory bowel diseases; aphthous-
like ulcers; probiotics
1. Introduction
The human gut contains a high concentration of bacteria, collectively called microbiota. There
are at least 1000 bacterial species (of which 150 to 500 only in the colon) with a density of 9 × 1013–14.
Several roles, related to the regulation of the host’s physiology, have been attributed to gut microbiota,
including stimulation of the immune system, control of pathogenic bacterial proliferation, production
of short-chain fatty acids, and fermentation of amino acids and saccharides [1,2].
A disequilibrium of the intestinal microbiota is called dysbiosis, and it causes an alteration of
the intercellular tight junctions, allowing access of pathogens (and their toxins, in particular bacterial
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lipopolysaccharides) and stimulation of the mucosa-associated lymphatic tissue (MALT) with activation
of the inflammatory cascade (leukocytes, cytokines, TNF-α), establishment of a chronic inflammation
process (Figure 1) and, consequently, tissue damage [1].
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  2 of 12 
 
lipopolysaccharides) and stimulation of the mucosa-associated lymphatic tissue (MALT) with 
activation of the inflammatory cascade (leukocytes, cytokines, TNF-α), establishment of a chronic 
inflammation process (Figure 1) and, consequently, tissue damage [1]. 
 
 
Figure 1. The delicate equilibrium between eubiosis and dysbiosis in the bowels. Eubiosis is the 
condition in which saprophytic bacteria are present in the mucus-microbiotic layer of the bowel 
(either the small or the large one). Dysbiosis is a condition in which pathogenic bacteria (Pathogenic 
bacteria are represented with purple frame, non-pathogenic have a blue frame) predominate and 
cause changes in the intercellular tight junctions and, in turn, activation of the MALT, leading to tissue 
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For this reason, dysbiosis has been implicated in the onset of several chronic autoimmune or 
inflammatory pathologies, including IBD (e.g., ulcerative colitis (UC) and Crohn’s disease (CD)), 
metabolic diseases (e.g., obesity, type diabetes 2 and nonalcoholic fatty liver disease), autoimmune 
diseases (e.g., rheumatoid arthritis, allergies, and systemic lupus erythematosus), and other disorders 
(e.g., food intolerances and even colorectal cancer) [1,3]; to date, only few studies linked dysbiosis to 
primary or secondary immunological oral mucosal disorders [4–6].  
The onset of extra-intestinal pathologies linked with dysbiosis is due to bacterial signals that 
affect the innate and adaptive immune system. These signals also involve type 3 innate lymphoid 
cells, which contribute to the differentiation of T and B cells and induce the production of Th17 cells 
through secretion of IL-22. Moreover, it has been shown that the intestinal microbiota influences the 
accumulation of IgA-producing cells in the lumen, and that IgA diversity in the intestine is related to 
changes in microbiota composition. The intestinal microbiota also promotes the differentiation of 
naive CD4+ T cells into Th17, which act at the epithelial level to improve the integrity of the intestinal 
mucosal barrier. This suggests that a disruption at this level can cause changes in the intestinal barrier 
and the onset of various pathologies [7] affecting not only the bowel (e.g., UC), but also other organs 
(i.e., arthritis, uveitis, etc.). 
1.1. Oral Manifestations in IBD 
Apart from the main symptoms related to the gastrointestinal involvement typical of IBD, these 
patients may present a broad spectrum of non-intestinal signs and symptoms known as 
extraintestinal manifestations (EIMs): joints, skin, eyes, the biliary tract and the oral mucosa are the 
most common sites involved [8]. 
Figure 1. The delicate equilibrium between eubiosis and dysbiosis in the bowels. Eubiosis is the
condition in which saprophytic bacteria are present in the mucus-microbiotic layer of the bowel (either
the small or the large one). Dysbiosis is a condition in which pathogenic bacteria (Pathogenic bacteria
are represented with purple frame, non-pathogenic have a blue frame) predominate and cause changes
in the intercellular tight junctions and, in turn, activation of the MALT, leading to tissue damage.
For this reason, dysbiosis has been implicated in the onset of several chronic autoimmune or
inflammatory pathologies, including IBD (e.g., ulcerative colitis (UC) and Crohn’s disease (CD)),
metabolic diseases (e.g., obesity, type diabetes 2 and nonalcoholic fatty liver disease), autoimmune
diseases (e.g., rheumatoid arthritis, allergies, and systemic lupus erythematosus), and other disorders
(e.g., food intolerances and even colorectal cancer) [1,3]; to date, only few studies linked dysbiosis to
primary or secondary immunological oral mucosal disorders [4–6].
The onset of extra-intestinal pathologies linked with dysbiosis is due to bacterial signals that
affect the innate and adaptive immune system. These signals also involve type 3 innate lymphoid
cells, which contribute to the differentiation of T and B cells and induce the production of Th17 cells
through secretion of IL-22. Moreover, it has been shown that the intestinal microbiota influences the
accumulation of IgA-producing cells in the lumen, and that IgA diversity in the intestine is related
to changes in microbiota composition. The intestinal microbiota also promotes the differentiation of
naive CD4+ T cells into Th17, which act at the epithelial level to improve the integrity of the intestinal
mucosal barrier. This suggests that a disruption at this level can cause changes in the intestinal barrier
and the onset of various pathologies [7] affecting not only the bowel (e.g., UC), but also other organs
(i.e., arthritis, uveitis, etc.).
1 1 Oral Manifesta ons in IBD
Apart from the main symptoms related to the gastrointestinal involvement typical of IBD, these
patients may present a broad spectrum of non-intestinal signs and symptoms known as extraintestinal
manifesta ions (EIMs): joints, skin, ey s, the biliary tract and he oral mucosa are the most common
sites involved [8].
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It is estimated that approximately one third of IBD patients may develop EIMs [9]; in particular,
oral lesions may anticipate or accompany gastrointestinal illness: patients with IBD may present
these manifestations years before the appearance of intestinal symptoms (5–10%), but EIMs are most
commonly diagnosed after intestinal involvement has occurred [10]. EIMs can sometimes be confused
with other extraintestinal complications related to IBD due to malnutrition, chronic inflammation or
side effects of drugs used to treat the disease itself [11].
The etiopathogenesis, classification, and natural history of muco-cutaneous disorders related to
IBD have not yet been well defined: in general, oral lesions are found more often in patients with CD
compared to UC, in children compared to adults and in males compared to females [8].
Differences may be found in the presentation of oral lesions between CD and UC: CD is
characterized by both specific and nonspecific oral lesions, while only nonspecific ones are found in UC.
In CD, oral lesions are defined as specific if the histopathologic data shows evidence of granulomas
(similar to those observed endoscopically in the intestine); these are less common than nonspecific
lesions (showed in Table 1) and they include: indurated tag-like lesions, cobblestoning, mucogingivitis,
lip swelling, deep linear ulcerations and midline lip fissuring (Table 2).
Table 1. Clinical characteristics of nonspecific oral lesions in CD.
Nonspecific Oral Lesions Clinical Presentation
Aphtous stomatitis Shallow, round ulcers surrounded by an erythematous halo witha central fibrin membrane
Angular cheilitis Erythema with/without painful fissures and sores at the cornersof the mouth
Glossitis Painful atrophy of the tongue
Pyostomatitis vegetans
Small exophytic lesions covered with a vulnerable membrane,
their cracking and confluence results in the characteristicsign of
a “snail track”
Oral Lichen/Oral Lichenoid reactions Associated to taste disturbances
Gingivitis/Periodontitis Associated to a vitamin D deficiency
Table 2. Clinical characteristics of specific oral lesions in CD.
Specific Oral Lesions Clinical Presentation
Indurated tag-like lesions (mucosal tags) White reticular tags (labial and buccal vestibules, retromolarregion)
Cobblestoning Fissured and corrugated swollen mucosa with hyperplasticappearance (posterior buccal mucosa)
Mucogingivitis Edematous, hyperplastic and granular gingiva (whole gingivaup to the mucogingival line)
Lip swelling Associated to vertical fissures
Deep linear ulcerations Associated to hyperplastic margins (vestibule)
Tongue and midline lip fissuring Lip and tongue fissures
In particular, cobblestoning and tag-like lesions are considered pathognomonic for CD, but these
are generally not associated with active intestinal disease [8]. Nonspecific oral lesions are found more
often than the specific ones, and are usually associated with CD and UC; these include recurrent
aphthae, angular cheilitis, pustular ulcerations, pyostomatitis vegetans, glossitis, lichen planus and
nonspecific gingivitis [12].
Among the nonspecific findings, recurrent aphthae are the most known oral lesions associated
with IBD; when the onset of aphthae is associated with systemic disorders, the term ALU is now
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considered preferable over the previously used RAS (recurrent aphthous stomatitis), since aphtae are
considered a secondary manifestation and the different clinical courses of the two conditions require
different management strategies [13]. ALU are reported to occur in up to 10% of UC and 25% of CD
patients, and they may become more severe in active disease; however, their presence or absence does
not correlate with disease activity [14]. Clinically, ALU are shallow, round or oval shaped lesions,
granular on palpation; they are often painful, leading to negative effects on patients’ daily activities [15].
Their onset is usually sudden and may be concurrent with a flare-up of intestinal symptoms, or appear
simultaneously with other EIMs [16]. Data from literature are conflicting in terms of the association
between ALU and the pathological activity: some studies link the presence of oral lesions with the
concomitant presence of intestinal symptoms, while other contradicting findings report no statistically
significant difference [17,18].
Deficiencies caused by diet or poor absorption of an essential nutrient can cause anaemia and
mineral and vitamin deficiency; in particular, vitamins B1, B2, B6, B12, iron, serum ferritin and folic acid
deficiencies have been reported in the pathogenesis of oral ulcers, implicating their role in weakening
the immune system [19]. Anaemia may also arise from chronic intestinal bleeding associated with
iron deficiency, causing angular cheilitis and painful depapillation of the tongue; constant iron and
zinc deficiencies may also be linked to erosive and crusty lesions on the lip commissures and perioral
region [20].
Regarding IBD therapy, all of the currently used drug classes have been linked to alterations in the
oral cavity due to their direct toxic effect on tissues and their indirect immunosuppressive effects [21].
1.2. Morphology: Comparative Microscopic Anatomy of Oral and Intestinal Mucosa
All the organs of the alimentary canal have a common origin in the primitive digestive gut. The
oral mucosa, that covers the entire oral cavity, consists of two layers: a stratified squamous epithelium
and an underlying connective tissue (lamina propria) that includes blood and lymphatic vessels,
as well as nerves and immune cells. However, the oral mucosa varies in structure, function and
appearance in different regions of the cavity, and it is divided into lining, masticatory and specialized
(gustative) mucosa [22,23], as detailed in Figure 2. Both the lining and masticatory oral mucosae may
host aphthous lesions.
The wall of the small and large bowel is canonically divided into four layers: mucosa, submucosa,
muscularis propria and serosa or adventitia. The mucosa is composed of epithelium, lamina propria
and muscularis mucosae. A simple columnar epithelium covers the small and large bowel (Figure 2),
although many regional differences are present [24–26].
The similarities between the oral and the intestinal mucosa include: (1) the presence of tight
junctions between epithelial cells; and (2) the presence of a basement membrane between the epithelium
and the lamina propria.
The equilibrium between the epithelium and the lamina propria is very important for mucosal
homeostasis, and both alterations in tight junctions and changes in basement membrane may result in
dysfunction of the mucosal barrier, as seen in inflammatory bowel disease [27].
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Figure 2. Comparison between oral (both lining and masticatory, respectively a,b) and bowel
(both small and large, respectively c,d) mucosae. Above: Original pictures, hematoxylin and eosin
stainings; bar: 100 micra. Original magnifications: 100×. Below: drawings summarizing the main
characteristics of these tissues. In detail, the epithelium of oral mu osa is a stratified squamous
epithelium, non-keratinized in the lining mucosa (a) and keratinized in the masticatory mucosa (b).
It is divided into four layers: basal layer, prickle-cell layer, intermediate layer and superficial layer for
lining mucosa; and basal layer, prickle-cell layer, granular layer and superficial (keratinizing) layer for
masticatory mucosa. In both epithelia, the basal layer consists of cuboidal or columnar keratinocytes
that are capable of division so as to maintain a constant epithelial population. Cells arising by division
in the basal layers of the epithelium undergo a process of maturation as they are passively displaced
toward the surface. In the non-keratinized squamous epithelium, the cytoplasm of intermediate cells
does not contain keratin filaments. In keratinizing epithelium, the granulosum stratum is prominent
and cells contain intracytoplasmic granules of keratohyaline. The epithelium of small bowel (c) covers
the intestinal villi and the crypt compartments; it is columnar and composed of various cell types, such
as absorptive cells, goblet cells and endocrine cells, in the villi, and stem cells and Paneth’s cells, in the
crypts. The epithelium of large bowel (d) covers glandular crypts; it is composed of a single layer
of columnar cells and consist of absorptive cells that are responsible of water and ion transport, and
goblet cells.
1.3. The Intestinal Microbiota and the Surrounding Mucous: The Fifth Layer of the Bowel Wall
As stated before, the wall of the bowel is canonically divided into four layers by morphologists
through the observation of histological sections after processing them with reagents, including alcohols
that remove mucus and other alcohol-soluble substances. However, in living subjects, the mucosal
layer is characterized by the presence of a mix of symbiotic and pathogenic bacteria embedded in
the mucus, produced by the epithelial cells. In this mucous matrix, apart from bacteria, are present a
number of soluble substances and nanovesicles (i.e., exosomes, microvesicles and outer membrane
vesicles), produced by both human cells and bacteria, that actively participate in the regulation of the
homeostasis of the intestinal mucosa and, consequently, through lymphatic and hematic circulation, of
virtually all of the organs [28–30]. Therefore, as already proposed [22], this mucus-microbiotic layer can
be considered the real innermost layer of the intestinal wall. The relevance of this hypothesis lies in the
fact that the understanding of the pathogenesis of human diseases derives from a precise knowledge of
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normal morphology, since many (if not all) pathologies derive from an alteration in cell differentiation
that, in turn, generates tissutal changes and loss of organ function; thus most (if not all) treatment
strategies should aim—when possible—to restore the normal morphology of the organs. The aim of
the present paper is to present a novel pathobiological hypothesis and, consequently, a non-invasive
therapeutic method.
2. Pathobiology of ALU in IBD and Therapeutic Proposal
2.1. Pathobiology: A Focus on Dysbiosis
The persistence of dysbiosis causes a state of chronic inflammation linked to the activation of
MALT and the release of inflammation mediators. This causes an onset of pathologies even in areas
that are physically far away from the gut [1–3].
Intestinal epithelial cells represent the main communication barrier between the host environment
and the microbiota, and also regulate the impact of the microbiota on the host immune function
(Figure 3).
For example, a healthy intestinal microbial flora promotes regulatory B (Breg) cell differentiation
and IL-1b and IL-6 production, and controls inflammatory processes through Breg cells and IL-10
secretion. Gut microbiota influences not only local, but also systemic immunity by bacterial metabolites
(such as ligands of aryl hydrocarbon receptor and polyamines) and bacterial components, such as
polysaccharide A, that exhibit immunomodulatory action [31]; moreover, studies carried out on animal
models have shown that intestinal dysbiosis may be related to the development of autoimmune diseases.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 12 
 
components, such as polysaccharide A, that exhibit immunomodulatory action [31]; moreover, 
studies carried out on animal models have shown that intestinal dysbiosis may be related to the 
development of autoimmune diseases. 
 
Figure 3. Aphthous-like ulcers: histopathological features. Left: These images show some typical 
features of ALU: round or oval ulcer covered by a yellow-white fibromembrane with a peripheral 
erythematous halo; margins may appear indurated and elevated (A: ALU in the right side of the 
tongue; B: ALU in the posterior buccal mucosa; C: Four concomitant ALU in the anterior buccal 
mucosa). Right: The ulcerative lesion shows an increased angiogenesis and a mixed inflammatory 
infiltrate that consists of various leukocytes (lymphocytes, neutrophils, monocytes and histiocytes). 
Mechanisms with which intestinal dysbiosis could generate autoimmune activation are not yet 
well understood. It is thought that they may be related to:  
-  Alteration of Treg/Th17 due to dysregulated TLRs on antigen-presenting cells [27]; 
-  Resistance to colonization, i.e., ability of the gut microbiota to limit the proliferation of 
external pathogens. It has been observed that in patients with autoimmune disorders (e.g., 
systemic lupus erythematosus), resistance to colonization was lower than in healthy controls; 
-  Superantigens, derived from bacteria and viruses that have the ability to activate immune 
cells by simultaneously binding to the major proteins of the class II histocompatibility 
complex (MHC II) present in the antigen-presenting cells and to specific receptors present in 
activated T cells [32]; 
-  Alteration of host antigens and overproduction of autoantigens; in particular, microbiota 
induces modification of host proteins and creation of neoantigens [27,33]; 
-  Mucosal responses to microbiota, i.e., inflammatory cytokines that activate nearby 
autoreactive cells [30]; 
-  Molecular mimicry, i.e., cross-reactive antibody that recognizes shared epitopes of microbial 
and host tissue proteins, and activation of autoreactive T and B cells [29,34,35]. 
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Figure 3. Aphthous-like ulcers: histopathological features. Left: These images show some typical
features of ALU: round or oval ulcer covered by a yellow-white fibromembrane with a peripheral
erythematous halo; margins may appear indurated and elevated (A: ALU in the right side of the tongue;
B: ALU in the posterior buccal mucosa; C: Four concomitant ALU in the anterior buccal mucosa). Right:
The ulcerative lesion shows an increased angiogenesis and a mixed inflammatory infiltrate that consists
of various leukocytes (lymphocytes, neutrophils, monocytes and histiocytes).
Mechanisms with which intestinal dysbiosis could generate autoimmune activation are not yet
well understood. It is thought that they may be related to:
Int. J. Mol. Sci. 2019, 20, 5026 7 of 12
- Alteration of Treg/Th17 due to dysregulated TLRs on antigen-presenting cells [27];
- Resistance to colonization, i.e., ability of the gut microbiota to limit the proliferation of external
pathogens. It has been observed that in patients with autoimmune disorders (e.g., systemic lupus
erythematosus), resistance to colonization was lower than in healthy controls;
- Superantigens, derived from bacteria and viruses that have the ability to activate immune cells by
simultaneously binding to the major proteins of the class II histocompatibility complex (MHC II)
present in the antigen-presenting cells and to specific receptors present in activated T cells [32];
- Alteration of host antigens and overproduction of autoantigens; in particular, microbiota induces
modification of host proteins and creation of neoantigens [27,33];
- Mucosal responses to microbiota, i.e., inflammatory cytokines that activate nearby autoreactive
cells [30];
- Molecular mimicry, i.e., cross-reactive antibody that recognizes shared epitopes of microbial and
host tissue proteins, and activation of autoreactive T and B cells [29,34,35].
Thus, the hypothesis we formulate is that ALU is the result of the concomitance of intestinal
dysbiosis (and consequent activation of the immune system) and other events, e.g., the microtraumas
occurring (frequently and for various causes) in the oral mucosa. Microtraumas can be considered
as a stress factor for oral mucosa that induce overexpression, trafficking and surface mislocalization
of intracellular proteins that may work, pathogenetically, as autoantigens. Heat shock proteins are
an example of intracellular proteins that—after cell stress—may be mislocalized to cell surface by
post-translational modifications that trigger unusual intracellular trafficking pathways; in addition,
bacterial Hsp60 homologous, i.e., GroEL, can induce the formation of antibodies against it that can
also cross-react against surface-exposed Hsp60, generating an autoimmune response by a molecular
mimicry mechanism [36–39].
2.2. ALU Treatment: Can Probiotics Be Useful?
In view of the above hypothesis, we suggest that an ex adiuvantibus therapy with probiotics could
be able to modify the natural course of ALU (Figure 4).
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Figure 4. Probiotics as effective therapy for ALU. Restoration of eubiosis can dramatically contribute to
remission of ALU by contrasting pathogenic phenomena. (Pathogenic bacteria are represented with
purple frame, non-pathogenic with a blue frame; the yellow and green frame indicate the bacterial
strains present after administration of probiotics).
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We cannot yet precisely answer the question “how do probiotics work?” but some theories can be
formulated. There are strong functional similarities between the gut and oral biofilms: it is reasonable
to speculate that corresponding health-promoting events may occur in the oral cavity to those already
reported in the gut. The oral cavity is a large reservoir of bacteria of >700 species and it is closely
related to host health and disease [40,41]. In a recent study, it is demonstrated an association between
dysbiosis of the salivary microbiota and IBD patients; it was observed that the salivary microbiota in
IBD patients significantly differed from that of healthy ones, and found particular bacterial species
associated with dysbiosis (Prevotella and Veillonella were significantly higher in both the CD and UC
groups while Streptococcus, Haemophilus, Neisseria and Gemella were significantly lower compared
with the healthy ones). It was also showed that the dysbiosis is strongly associated with elevated
inflammatory response of several cytokines with depleted lysozyme in the saliva of IBD patients [42].
In the oral cavity, probiotics create a biofilm which matches with carcinogenic bacteria and periodontal
pathogens modulating host immune response by strengthening the immune system [43]. There are
local (direct) as well as systemic (indirect) events that occur by regulation of the immune response.
The potential pathways could include [44]:
- Co-aggregation and growth inhibition;
- Bacteriocin and hydrogen peroxide production;
- Competitive exclusion through antagonistic activities on adhesion and nutrition;
- Immunomodulation.
There is an increasing body of evidence suggesting that perturbations of mucosal microbiota can
modulate innate and adaptive immune responses, with inflammation arising upon reduction of the
number of symbiont microorganisms and/or increase in the number of pathobiont microorganisms
(commensal bacteria with pathogenic potential) [45].
Several immune mechanisms, implicated in the remission of ALU, by symbiont bacteria have
been hypothesized, including induction of IL-10, suppression of TNF-α and IL-8, and modulation of
Toll-like receptors [46].
This hypothesis has been reinforced by some studies that correlate the administration of probiotics
to the improvement of autoimmune diseases. For example, it has been observed that in patients
with rheumatoid arthritis, the administration of Lactobacillus casei increased the serum levels of IL-10
anti-inflammatory cytokine and decreased the levels of proinflammatory cytokines such as TNF-alpha,
IL-6 and IL-12 [27].
3. Conclusions
Intestinal dysbiosis causes a chronic inflammatory state and activation of the MALT in the gut,
which leads to the onset of extraintestinal pathologies [1–3]. We hypothesized that ALU could also be
caused by intestinal dysbiosis, due to the immunological mechanisms involved in the pathogenesis of
the disease [27] and the fact that there are several immune mechanisms implicated in the remission
of ALU mediated by symbiont bacteria [36]. By comparing what happens in the intestine [47],
we hypothesize that the administration of probiotics can increase the expression of tight junction
protein ZO-1, both in terms of transcriptome and protein synthesis, with an improve intestinal
barrier function. In fact, it was shown as a result of a chronic inflammatory state levels of TNF-α,
IFN-γ and IL-23 stimulate the epithelial barrier breakdown, affecting in particular the expression of
proteins forming the tight junctions. This increase can be countered by administering specific probiotic
strains including Lactobacillus salivarius, Bifidobacterium lactis, Lactobacillus Plantarum and Lactobacillus
fermentum [48,49]. In addition to antagonistic act on proinflammatory cytokines, microbial metabolites
directly promote the synthesis of the aforementioned tight junction proteins through activation of aryl
hydrocarbon receptor, with subsequent activation of nuclear factor erythroid 2–related factor 2 (Nrf2)
which has as a final result just the increased synthesis of ZO-1 with consequent strengthening of the
epithelial barrier [50].
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Therefore, we proposed the use of probiotics as direct therapy for intestinal dysbiosis and as
an indirect one for ALU. In particular, preliminary observations lead us to suggest that the therapy
with probiotics should be started when the patient first starts to experience the ALU symptoms. Our
hypothesis is that this therapy can reduce the duration of the disease by up to three days, through
limiting the development of the lesion and favouring the re-epithelization of the lesioned oral cavity
mucosa thanks to the molecular mechanisms discussed above (Figure 5).
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contribute to remission of ALU by contrasting pathogenic phenomena.
Experimental and clinical evidence on the use of probiotics for the treatment of oral aphthae
are currently very limited, and the etiology and pathogenesis of ALU is currently unknown. So, we
think that it would be opportune to carry out in depth studies of this phenomenon, taking into
account that host genetics, nutritional deficiencies, and a number of systemic conditions have been
recognized as systemic modulating factors of ALU [34,51]. Further studies are needed to establish
which immunological mechanisms can be implicated in ALU pathogenesis and modulated by the
administration of probiotics.
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